Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling

British Journal of Pharmacology

Volumn 172, Issue 14, 2015, Pages 3627-3637

  Rinaldi, Barbara ^a   Donniacuo, Maria ^a   Sodano, Loredana ^a   Gritti, Giulia ^a   Martuscelli, Eugenio ^b   Orlandi, Augusto ^b   Rafaniello, Concetta ^a   Rossi, Francesco ^a   Calzetta, Luigino ^b   Capuano, Annalisa ^a   Matera, Maria Gabriella ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR KINASE 2; INDACATEROL; MESSENGER RNA; METOPROLOL; NORADRENALIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EXPERIMENTAL MODEL; GENE EXPRESSION; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE DIASTOLIC INTERNAL DIAMETER; HEART LEFT VENTRICLE SYSTOLIC INTERNAL DIAMETER; HEART MUSCLE; HEART RATE; HEART REMODELING; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TISSUE LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; ANIMAL; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HEART VENTRICLE REMODELING; METABOLISM; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; WISTAR RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEART FAILURE; HEART RATE; INDANS; MALE; METOPROLOL; MYOCARDIAL INFARCTION; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; VENTRICULAR REMODELING;

EID: 84933053414     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13148     Document Type: Article

References (59)

1. Adameova A, Abdellatif Y, Dhalla NS, (2009). Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol 87: 493-514.
2. Aguero J, Almenar L, Monto F, Oliver E, Sanchez-Lazaro I, Vicente D, et al. (2012). Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J Card Fail 18: 53-61.
3. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI, (2004). Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110: 1083-1090.
4. Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, Poosala S, et al. (2008). Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 325: 491-499.
5. Ahmet I, Morrell C, Lakatta EG, Talan MI, (2009). Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 331: 178-185.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
8. Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, et al. (2006). In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-o ne (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762-770.
9. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. (1986). Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59: 297-309.
10. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, et al. (2013). Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 346: 414-423.
11. Cazzola M, Calzetta L, Matera MG, (2011). Beta(2)-adrenoceptor agonists: current and future direction. Br J Pharmacol 163: 4-17.
12. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, et al. (2013). Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med 107: 848-853.
13. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, et al. (2014a). Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on Human isolated bronchi. Eur J Pharmacol 745: 135-143.
14. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG, (2014b). Translational study searching for synergy between glycopyrronium and indacaterol. COPD 1-7.
15. Clark RB, Rich TC, (2003). Probing the roles of protein kinases in g-protein-coupled receptor desensitization. Mol Pharmacol 64: 1015-1017.
16. Cohn JN, Ferrari R, Sharpe N, (2000). Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35: 569-582.
17. Eaton LW, Bulkley BH, (1981). Expansion of acute myocardial infarction: its relationship to infarct morphology in a canine model. Circ Res 49: 80-88.
18. EMEA (2009). Assessment report for hirobriz breezhaler. European Medicines Agency, Evaluation of Medicines for Human Use Doc.Ref.: EMA/814999/2009; Procedure No. EMEA/H/C/001211.
19. Ferlosio A, Arcuri G, Doldo E, Scioli MG, De Falco S, Spagnoli LG, et al. (2012). Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 224: 51-57.
20. Floras JS, (2002). The 'unsympathetic' nervous system of heart failure. Circulation 105: 1753-1755.
21. George I, Xydas S, Mancini DM, Lamanca J, DiTullio M, Marboe CC, et al. (2006). Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. J Heart Lung Transplant 25: 1084-1090.
22. GOLD (2014). Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (updated 2014). Available at: http://www.goldcopd.org/uploads/users/files/GOLD-Report-2014-Jan23.pdf (accessed 10/3/2015).
23. Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV, (2012). G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 133: 40-69.
24. Hochman JS, Bulkley BH, (1982). Expansion of acute myocardial infarction: an experimental study. Circulation 65: 1446-1450.
25. Kassner A, Toischer K, Bohms B, Kolkhof P, Abraham G, Hasenfubeta G, et al. (2012). Regulation of cyclic adenosine monophosphate release by selective beta2-adrenergic receptor stimulation in human terminal failing myocardium before and after ventricular assist device support. J Heart Lung Transplant 31: 1127-1135.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
27. Korup E, Dalsgaard D, Nyvad O, Jensen TM, Toft E, Berning J, (1997). Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction. Am J Cardiol 80: 449-453.
28. Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, et al. (2013). Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol 61: 54-63.
29. Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, et al. (2006). Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharma Bull 29: 1756-1758.
30. Larj MJ, Bleecker ER, (2002). Effects of beta2-agonists on airway tone and bronchial responsiveness. J Allergy Clin Immunol 110 (6 Suppl.): S304-S312.
31. Lombardi D, Cuenoud B, Kramer SD, (2009). Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 38: 533-547.
32. Lymperopoulos A, (2011). GRK2 and beta-arrestins in cardiovascular disease: something old, something new. Am J Cardiovasc Dis 1: 126-137.
33. Matera MG, Martuscelli E, Cazzola M, (2010). Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther 23: 1-8.
34. Matera MG, Calzetta L, Cazzola M, (2013). beta-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs 73: 1653-1663.
35. Matera MG, Rogliani P, Cazzola M, (2014). Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 15: 961-977.
36. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, et al. (2006). Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res 99: 996-1003.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R, (2013). The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis 8: 305-312.
39. Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, Insel PA, (2001). Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem 276: 42063-42069.
40. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
41. Pfeffer MA, Braunwald E, (1990). Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172.
42. Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, et al. (2008). G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 103: 413-422.
43. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, et al. (2009). Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119: 89-98.
44. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, Mazzon E, et al. (2011). PPARalpha mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br J Pharmacol 163: 609-623.
45. Rinaldi B, Donniacuo M, Sodano L, Gritti G, Signoriello S, Parretta E, et al. (2013). Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training. PLoS ONE 8: e69954.
46. Rinaldi B, Capuano A, Gritti G, Donniacuo M, Scotto Di Vettimo A, Sodano L, et al. (2014). Effects of chronic administration of beta-blockers on airway responsiveness in a murine model of heart failure. Pulm Pharmacol Ther 28: 109-113.
47. Robey RB, Ruiz OS, Baniqued J, Mahmud D, Espiritu DJ, Bernardo AA, et al. (2001). SFKs, Ras, and the classic MAPK pathway couple muscarinic receptor activation to increased Na-HCO(3) cotransport activity in renal epithelial cells. Am J Physiol Renal Physiol 280: F844-F850.
48. Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, et al. (2013). The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm Pharmacol Ther 26: 325-331.
49. Sabbah HN, (2004). Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev 9: 91-97.
50. Sato Y, Kita T, Takatsu Y, Kimura T, (2004). Biochemical markers of myocyte injury in heart failure. Heart 90: 1110-1113.
51. Sato Y, Fujiwara H, Takatsu Y, (2012). Biochemical markers in heart failure. J Cardiol 59: 1-7.
52. Soppa GK, Smolenski RT, Latif N, Yuen AH, Malik A, Karbowska J, et al. (2005). Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol 288: H1468-H1476.
53. Soppa GK, Lee J, Stagg MA, Felkin LE, Barton PJ, Siedlecka U, et al. (2008). Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 77: 695-706.
54. Spitalieri P, Quitadamo MC, Orlandi A, Guerra L, Giardina E, Casavola V, et al. (2012). Rescue of murine silica-induced lung injury and fibrosis by human embryonic stem cells. Eur Respir J 39: 446-457.
55. Sun Y, Weber KT, (2000). Infarct scar: a dynamic tissue. Cardiovasc Res 46: 250-256.
56. Suurmeijer AJ, Clement S, Francesconi A, Bocchi L, Angelini A, Van Veldhuisen DJ, et al. (2003). Alpha-actin isoform distribution in normal and failing human heart: a morphological, morphometric, and biochemical study. J Pathol 199: 387-397.
57. Talan MI, Ahmet I, Xiao RP, Lakatta EG, (2011). beta(2) AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol 51: 529-533.
58. Weisman HF, Bush DE, Mannisi JA, Bulkley BH, (1985). Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol 5: 1355-1362.
59. Xydas S, Kherani AR, Chang JS, Klotz S, Hay I, Mutrie CJ, et al. (2006). beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy. J Pharmacol Exp Ther 317: 553-561.